Mukka Proteins: consolidated PAT up 157.5% YoY to ₹17.7 Cr on export surge, dips 4.9% QoQ on tax
PAT +157.53% YoY · revenue +108.06% · margins expanding
₹508.87 Cr
+108.06% YoY
₹17.73 Cr
+157.53% YoY
3.42%
+0.7pp YoY
₹0.53
Mukka Proteins' consolidated PAT came in at ₹17.73 Cr for Q2 FY27, up 157.5% YoY from ₹6.88 Cr, on revenue of ₹508.87 Cr, up 108.1% YoY from ₹244.58 Cr. Sequentially the picture is softer: revenue rose a modest 3.9% QoQ but PAT fell 4.9% QoQ from ₹18.63 Cr.
Q2 FY-2027 vs prior quarters
The YoY story is a genuine net-margin expansion — NPM improved to 3.42% from 2.75% a year ago — while OPM was roughly steady (8.31% vs 8.47%). The QoQ dip, however, is not an operating story at all: PBT was virtually flat sequentially at ₹27.38 Cr versus ₹27.37 Cr in Q1 FY27. The entire sequential PAT decline traces to the tax line, where the effective rate jumped to ~35.3% from ~31.9% in Q1 (deferred tax nearly doubled to ₹4.54 Cr from ₹2.55 Cr). Standalone (parent-only) PAT grew ~196% YoY to ₹10.70 Cr — well ahead of the 157.5% consolidated growth — meaning subsidiaries and joint ventures collectively diluted group profit growth this quarter, consistent with the ₹1.19 Cr associates/JV share-of-loss booked (versus ₹0.45 Cr a year ago).
The stock went into the print at ₹29.53, up 7.3% over the past month of trading.
No brokerage previews or consensus estimates for this quarter turned up in search — this is a micro-cap with no visible formal analyst coverage — so the print cannot be graded against street expectations, and management has issued no prior formal guidance on record either. Export sales drove the topline: consolidated revenue from outside India rose to ₹413.51 Cr from ₹141.36 Cr a year ago, while India revenue actually fell to ₹81.77 Cr from ₹94.72 Cr. That lines up with a cluster of export-facing approvals this quarter — US FDA facility registration (Oct 27) and a USDA NOP inputs attestation (Oct 6) — and a subsidiary that began commercial production in Oman on Oct 9, backed by a ₹73.58 Cr parent guarantee on its credit facility. The company also drew ₹11.75 Cr (25% upfront) of a ₹47 Cr convertible-warrant issue (2 crore warrants at ₹23.50 each) this quarter, funding a step-up in capex — consolidated gross block rose to ₹195.1 Cr from ₹163.9 Cr at FY26-end.
W1
Effective tax rate: jumped to ~35.3% in Q2 FY27 from ~31.9% in Q1 FY27 — watch whether it normalizes in Q3
W2
Oman subsidiary ramp-up after commercial production start (Oct 9, 2026), backed by a ₹73.58 Cr parent guarantee on its credit facility
W3
Aqua Marine acquisition, now targeted for completion by January 2027 after being delayed from its original timeline
Figures in ₹ Million in source, converted to ₹ Crore (÷10); no exceptional items in either period. Consolidated PAT (₹17.73 Cr) includes ₹1.74 Cr non-controlling interest and a ₹1.19 Cr share-of-loss from associates/JVs; reported EPS (₹0.53) is computed on the ₹15.99 Cr profit attributable to owners, not total PAT.